 |
20 Diseases |  |
17 Trials |
|
17 Trials |  |
3666 News |  |
| «12...31323334353637383940414243» |
- | Symbicort (budesonide) / AstraZeneca, Foradil Aerolizer (formoterol dry powder inhaler) / Novartis
Clinical, Journal: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study. (Pubmed Central) - Apr 24, 2019
P=N/A, P4
An exploratory independent expert-verified analysis found Spiromax was associated with higher levels of device mastery after 12 weeks. Asthma control was improved by treatment with both BF Spiromax and BF Turbuhaler.
- | budesonide / generics
Review, Journal: The Gut-Renal Connection in IgA Nephropathy. (Pubmed Central) - Apr 24, 2019
After 9 months of treatment, a reduction in proteinuria was observed with stabilized renal function and limited adverse events. The gut-renal connection is an area of promising new treatment approaches for patients with IgAN.
- | budesonide / generics
Journal: Preference of diagnostic tools, medications, and devices for asthma management: A survey of doctors in Algeria. (Pubmed Central) - Apr 23, 2019
...Budesonide (86%), fluticasone (46%), and beclomethasone (40%) were the most prescribed inhaled corticosteroid (ICS) by doctors...Most of the doctors managed asthma in accordance with the global initiative for asthma guidelines. Spacers were found to be less prescribed in regular treatment, despite having good awareness about its better outcomes.
- | budesonide / generics
Journal: Every Other Day Dosing of Oral Viscous Budesonide is not Effective in the Management of Eosinophlic Esophagitis. (Pubmed Central) - Apr 19, 2019
A MWF dosing regimen of OVB was not effective at maintaining histologic response in children and adolescents with EoE. Larger prospective studies are warranted to confirm these results.
- | dexamethasone / generics, tacrolimus / generics
Journal: Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. (Pubmed Central) - Apr 18, 2019
Larger prospective studies are warranted to confirm these results. High-quality evidence assessing conventional therapy in MS-IBD treatment is scarce, especially for remission maintenance, mucosal healing and fecal calprotectin.
- | pilaralisib (SAR245408) / Sanofi, selumetinib (AZD6244) / Merck (MSD), AstraZeneca
Biomarker, PK/PD data, Journal: Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma. (Pubmed Central) - Apr 18, 2019
High-quality evidence assessing conventional therapy in MS-IBD treatment is scarce, especially for remission maintenance, mucosal healing and fecal calprotectin. This is the first study to use circulating exosomal miRNAs as pharmacodynamic biomarkers for CPA treatment in lung cancer.
- | Clinical, Review, Journal: Antibiotics for induction and maintenance of remission in Crohn's disease. (Pubmed Central) - Apr 13, 2019
Thus, no firm conclusions regarding the efficacy and safety of antibiotics for maintenance of remission in CD can be drawn. More research is needed to determine the efficacy and safety of antibiotics as therapy in CD.
- || budesonide / generics
Could be tried but in my experience not strong enough. Have had one success with 15mg budesonide open capsule. But with milder disease. (Twitter) - Apr 13, 2019
- || budesonide / generics
Wonder if the new orodispersable budesonide (jorveza) might prove useful in this situation (Twitter) - Apr 13, 2019
- || budesonide / generics
Nope. That study compares daily buddsonide to intermittent. No arm of nothing but fact daily made no difference over intermittent brings into question of usefulness of budesonide (Twitter) - Apr 13, 2019
- | budesonide / generics
Preclinical, Journal: Budesonide and Calcitriol Synergistically Inhibit Airway Remodeling in Asthmatic Mice. (Pubmed Central) - Apr 12, 2019
VDR expression in the combined treatment group was significantly higher than that of the calcitriol treatment group. Budesonide and calcitriol have a synergistic effect on airway remodeling in asthmatic mice.
- | Striverdi Respimat (olodaterol) / Boehringer Ingelheim
Review, Journal: Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes. (Pubmed Central) - Apr 12, 2019
In this review, we describe these pharmacokinetic processes and explain how they may be influenced by drug-, formulation- and device-, and patient-related factors. Furthermore, we highlight the complex interplay between these processes and describe, using the examples of inhaled albuterol, fluticasone propionate, budesonide, and olodaterol, how various sequential or parallel pulmonary processes should be considered in order to comprehend the pulmonary fate of inhaled drugs.
- | budesonide / generics
Journal: Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children with Eosinophilic Esophagitis. (Pubmed Central) - Apr 11, 2019
Adherence to treatment and history of asthma are major determining factors in the response to treatments. Using Neocate® Duocal as the OVB delivery vehicle is just as effective as sucralose.
- | budesonide / generics
Clinical, Journal: Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan. (Pubmed Central) - Apr 11, 2019
...Fluticasone/salmeterol use tended to show a higher risk of pneumonia than budesonide/formoterol use...In regard to pneumonia, ICS can be safely used in Japanese patients with COPD. Because there are apparent differences in lung diseases among races, appropriate treatment should be investigated in each country.
- | budesonide / generics
Clinical, Journal: Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. (Pubmed Central) - Apr 5, 2019
These in vitro results are discussed in light of clinical data. ColoPulse 3 mg and 9 mg are novel interesting formulations for the treatment of the entire ileo-colon in inflammatory bowel disease.
- | Retrospective data, Review, Journal: Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. (Pubmed Central) - Apr 3, 2019
Budesonide MMX is associated with less corticosteroid-related AEs than its comparator steroid treatments for adult IBD patients. Further high-quality research is warranted to illuminate the steroid drugs' comparative safety profiles.
- | budesonide / generics
Clinical, Journal: The impact of inhaled bronchodilators on bronchopulmonary dysplasia: a nonrandomized comparison from the NEuroSIS trial. (Pubmed Central) - Mar 30, 2019
Further high-quality research is warranted to illuminate the steroid drugs' comparative safety profiles. Based on our analyses, early inhaled bronchodilators did not reduce the risk of BPD and death in extremely preterm infants.
- | budesonide / generics
The main pharmacological treatments for EoE continue to be: PPIs. Swallowed topical steroids like budesonide nebules mixed with Splenda, or maple syrup 🇨🇦! Systemic steroid. Non-pharmacologic: Dietary avoidance (Twitter) - Mar 30, 2019
- | Symbicort (budesonide) / AstraZeneca
Journal: Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort (budesonide/formoterol) pressurized metered dose inhaler. (Pubmed Central) - Mar 29, 2019
P1
The clinical study demonstrated that in subjects with poor inhalation technique the use of the AeroChamber Plus Flow-Vu spacer increased the bioavailability of Symbicort pMDI to a level observed in subjects with good inhalation technique without a spacer. The findings from the in vitro study support the fine particle dose characteristics of Symbicort pMDI with the AeroChamber Plus Flow-Vu spacer.
- | Onbrez (indacaterol) / Novartis
Journal: The Effects of asthma medications on reactive oxygen species production in human monocytes. (Pubmed Central) - Mar 27, 2019
Montelukast may be also a good supplemental treatment for the poorly-controlled asthma because of its powerful anti-ROS effects. Our findings provide a novel therapeutic view in asthma.
- | budesonide / generics
Clinical, Journal: Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18Â years. (Pubmed Central) - Mar 27, 2019
Eosinophil levels in induced sputum correlate well with clinical asthma parameters and asthma severity in children. It is a simple, noninvasive and cheap method which can be used for the monitoring of asthma in a resource-limited setting.
- | Halog (halcinonide) / Sun Pharma
Journal: Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. (Pubmed Central) - Mar 23, 2019
Three drug families presenting with multiple hits, namely antihistamines (astemizole and terfenadine), cardiac glycosides (strophanthidin, digoxin and ouabain) and glucocorticoids (budesonide, halcinonide and mometasone), were validated for their activity against human primary AML samples. Our study demonstrates the efficacy of combining computational analysis of stem cell gene expression signatures with in vitro screening to identify novel compounds that target the therapy-resistant LSC at the root of relapse in AML.
- | budesonide / generics
Clinical, Journal, HEOR: Effects of Budesonide Combined with Noninvasive Ventilation on PCT, sTREM-1, Chest Lung Compliance, Humoral Immune Function and Quality of Life in Patients with AECOPD Complicated with Type II Respiratory Failure. (Pubmed Central) - Mar 20, 2019
Budesonide combined with noninvasive mechanical ventilation has good curative effects in treating AECOPE patients complicated with type II respiratory failure. It can decrease serum PCT and sTREM-1, increase thoracic lung compliance, and improve the humoral immune function and life quality.
- | budesonide / Generic mfg.
New P4 trial: Budesonide in Patients With Immune Mediated Enteropathies (clinicaltrials.gov) - Mar 7, 2019
P4, N=20, Not yet recruiting, Sponsor: Mayo Clinic
- | Trial completion date: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Feb 4, 2019
P=N/A, N=50, Active, not recruiting, Sponsor: University of Maryland
It can decrease serum PCT and sTREM-1, increase thoracic lung compliance, and improve the humoral immune function and life quality. Trial completion date: Dec 2018 --> Jul 2019
- | Gattex (teduglutide) / Takeda
New P2 trial: TAME: Therapeutic Approaches to Malnutrition Enteropathy (clinicaltrials.gov) - Oct 22, 2018
P2, N=235, Not yet recruiting, Sponsor: Queen Mary University of London
- | Trial completion date: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Oct 12, 2018
P=N/A, N=50, Active, not recruiting, Sponsor: University of Maryland
Trial completion date: Dec 2018 --> Jul 2019 Trial completion date: Jun 2018 --> Dec 2018
- | prednisone / Generic mfg., budesonide / Generic mfg.
Trial completion date: Budesonide for Liver Transplant Immune Suppression (clinicaltrials.gov) - Oct 11, 2018
P2, N=20, Recruiting, Sponsor: University of Cincinnati
Trial completion date: Jun 2018 --> Dec 2018 Trial completion date: Dec 2018 --> Mar 2019
- | Nerlynx (neratinib) / Puma
Enrollment change: CONTROL: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide (clinicaltrials.gov) - Aug 21, 2018
P2, N=650, Recruiting, Sponsor: Puma Biotechnology, Inc.
Trial completion date: Dec 2018 --> Mar 2019 N=312 --> 650
- | NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: Eosinophilic Esophagitis Clinical Therapy Comparison Trial (clinicaltrials.gov) - Jul 19, 2018
P2, N=60, Active, not recruiting, Sponsor: Baylor College of Medicine
N=312 --> 650 Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2017 --> Mar 2019
- | budesonide / Generic mfg.
Enrollment change, Trial initiation date, Trial withdrawal, Adverse events: BILT: Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects (clinicaltrials.gov) - Jun 13, 2018
P4, N=0, Withdrawn, Sponsor: Montefiore Medical Center
Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2017 --> Mar 2019 N=100 --> 0 | Initiation date: Jan 2018 --> Jan 2019 | Not yet recruiting --> Withdrawn
- | budesonide / Generic mfg.
Retrospective data, Review, Journal: Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. (Pubmed Central) - Apr 26, 2018
The analyses included 16 randomized clinical trials (N = 22 748 patients), 15 of which evaluated SMART as a combination therapy with budesonide and formoterol in a dry-powder inhaler...In this meta-analysis of patients with persistent asthma, the use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was associated with a lower risk of asthma exacerbations. Evidence for patients aged 4 to 11 years was limited.
- | Trial primary completion date: APRiCCOT: Antibiotics and Hydroxychloroquine in Crohn's (clinicaltrials.gov) - Apr 17, 2018
P2, N=100, Recruiting, Sponsor: Royal Liverpool University Hospital
Evidence for patients aged 4 to 11 years was limited. Trial primary completion date: Dec 2015 --> Dec 2019
- | budesonide / Generic mfg.
Trial completion date, Trial primary completion date: Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients (clinicaltrials.gov) - Apr 5, 2018
P2, N=30, Recruiting, Sponsor: Pooja Budhiraja, MD
Trial primary completion date: Dec 2015 --> Dec 2019 Trial completion date: Apr 2018 --> Apr 2019 | Trial primary completion date: Apr 2018 --> Apr 2019
- |||||| budesonide / Generic mfg.
Enrollment open: To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis (clinicaltrials.gov) - Mar 21, 2018
P3, N=273, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial completion date: Apr 2018 --> Apr 2019 | Trial primary completion date: Apr 2018 --> Apr 2019 Not yet recruiting --> Recruiting
- | budesonide / Generic mfg.
Preclinical, Journal: Ex Vivo CD34+ Selected T-Cell Depleted (TCD) Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) and High Treatment Response. (Pubmed Central) - Mar 3, 2018
Patients were treated with topical corticosteroids, poorly absorbed corticosteroids (budesonide), and/or systemic corticosteroids...The 1-year and 3-years probability of cGVHD-free/relapse-free survival (CRFS) were 65% (95% CI:59-71) and 52% (95% CI:45-59), respectively. Our findings support the use of ex vivo CD34+ selected TCD allograft as a calcineurin inhibitor-free intervention for the prevention of GVHD in patients with acute leukemia and MDS.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=50, Active, not recruiting, Sponsor: University of Maryland
Our findings support the use of ex vivo CD34+ selected TCD allograft as a calcineurin inhibitor-free intervention for the prevention of GVHD in patients with acute leukemia and MDS. Recruiting --> Active, not recruiting | N=90 --> 50 | Trial primary completion date: Aug 2016 --> Jun 2018 | Trial completion date: Aug 2017 --> Jun 2018
- |||||||||| budesonide / Generic mfg.
New P3 trial: To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis (clinicaltrials.gov) - Jan 26, 2018
P3, N=273, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- ||| Nerlynx (neratinib) / Puma
Enrollment change, Trial primary completion date: CONTROL: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide (clinicaltrials.gov) - Dec 6, 2017
P2, N=312, Recruiting, Sponsor: Puma Biotechnology, Inc.
Recruiting --> Active, not recruiting | N=90 --> 50 | Trial primary completion date: Aug 2016 --> Jun 2018 | Trial completion date: Aug 2017 --> Jun 2018 N=240 --> 312 | Trial primary completion date: Jan 2019 --> Feb 2020
- | budesonide / Generic mfg.
Journal: Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery. (Pubmed Central) - Dec 1, 2017
Concomitant use of both nasal steroid sprays and pulmonary steroid inhalers while using daily budesonide nasal irrigations is associated with an increased risk. Rhinologists should be alerted to the potential risks of long-term use of budesonide nasal irrigations, and monitoring for HPAA suppression may be warranted in patients receiving long-term budesonide irrigation therapy.
- | budesonide / Generic mfg.
New P4 trial, Adverse events: BILT: Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects (clinicaltrials.gov) - Oct 19, 2017
P4, N=100, Not yet recruiting, Sponsor: Montefiore Medical Center
- | prednisone / Generic mfg., budesonide / Generic mfg.
New P2 trial: Budesonide for Liver Transplant Immune Suppression (clinicaltrials.gov) - Oct 8, 2017
P2, N=20, Recruiting, Sponsor: University of Cincinnati
- | budesonide / Generic mfg., voriconazole / Generic mfg.
Enrollment change: Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease (clinicaltrials.gov) - Sep 19, 2017
P1, N=21, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Rhinologists should be alerted to the potential risks of long-term use of budesonide nasal irrigations, and monitoring for HPAA suppression may be warranted in patients receiving long-term budesonide irrigation therapy. N=27 --> 21
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, budesonide / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Expert clinical management of autoimmune hepatitis in the real world. (Pubmed Central) - Aug 17, 2017
Although good quality evidence is lacking, there is considerable experience with second-line therapies. Future prospective studies should address these issues, so that we move from an expert- to an evidence- and personalised-based care in autoimmune hepatitis.
- | budesonide / Generic mfg.
Journal: Open-Capsule Budesonide for Refractory Celiac Disease. (Pubmed Central) - Aug 16, 2017
Most patients with RCD show clinical and histopathologic improvement with OB therapy, including those with failure of IMs. OB is a promising therapeutic option for management of RCD.
- | budesonide / Generic mfg.
Trial completion, Enrollment change, Trial initiation date: Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis (clinicaltrials.gov) - May 31, 2017
P1, N=22, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
OB is a promising therapeutic option for management of RCD. Active, not recruiting --> Completed | N=50 --> 22 | Initiation date: Oct 1998 --> May 1997
- budesonide / Generic mfg.
Enrollment open: Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients (clinicaltrials.gov) - Feb 2, 2017
P2, N=30, Recruiting, Sponsor: Pooja Budhiraja, MD
Active, not recruiting --> Completed | N=50 --> 22 | Initiation date: Oct 1998 --> May 1997 Not yet recruiting --> Recruiting
- | NN1213 / Novo Nordisk, Nutropin AQ (somatropin) / Ipsen, Roche
Trial completion: Trial of Growth Hormone Therapy in Pediatric Crohn's Disease (clinicaltrials.gov) - Jan 11, 2017
P2, N=22, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Nerlynx (neratinib) / Puma
Enrollment change, Trial primary completion date: CONTROL: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide (clinicaltrials.gov) - Jan 11, 2017
P2, N=240, Recruiting, Sponsor: Puma Biotechnology, Inc.
Active, not recruiting --> Completed N=120 --> 240 | Trial primary completion date: Oct 2016 --> Jan 2019
- budesonide / Generic mfg.
New P2 trial: Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients (clinicaltrials.gov) - Dec 13, 2016
P2, N=30, Not yet recruiting, Sponsor: Pooja Budhiraja, MD